Last reviewed · How we verify
Epratuzumab iv
At a glance
| Generic name | Epratuzumab iv |
|---|---|
| Also known as | CDP3194, EMAB |
| Sponsor | UCB Biopharma S.P.R.L. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epratuzumab iv CI brief — competitive landscape report
- Epratuzumab iv updates RSS · CI watch RSS
- UCB Biopharma S.P.R.L. portfolio CI